



Q4 and Fiscal Year 2025 Year End

Results Presentation



Disclosures

Disclaimer

This presentation is not, & nothing in it should be construed as, an offer, invitation or recommendation in respect of ImmunoPrecise Antibodies Ltd. (the “Company”) securities, or an offer, invitation or recommendation to sell, or solicitation of an offer to buy, the facilities or of the Company’s securities in any jurisdiction . Neither this presentation nor anything in it shall form the basis of any contract or commitment. This presentation is not intended to be relied upon as advice to investors or potential investors & does not take into account the investment objectives, financial situation or needs of any investor. All investors should consider such factors in consultation with a professional advisor of their choosing when deciding if an investment is appropriate. The Company has prepared this presentation based on information available to it, including information derived from public sources that have not been independently verified. No representation or warranty, express or implied, is provided in relation to the fairness, accuracy, correctness, completeness or reliability of the information, opinions or conclusions expressed herein. These projections should not be considered a representation of the Company’s potential cash generation performance in any way.

Forward Looking Statements

This presentation includes forward-looking statements (within the meaning of applicable securities laws) to provide prospective investors with information pertaining to the Company’s long-term business objective. Forward-looking statements often, but not always, are identified by the use of words such as “seek”, “anticipate”, “believe”, “plan”, “estimate”, “expect”, “targeting” and “intend” and statements that an event or result “may”, “will”, “should”, “could”, or “might” occur or be achieved and other similar expressions.

Forward-looking statements are not statements of historical fact or assurances of future performance. They are based on the current beliefs, expectations & assumptions of the Company’s management about the Company’s business, planned acquisitions, future plans, anticipated events & other future conditions. All forward-looking statements attributable to the Company or persons acting on its behalf apply only as of the date of this document & are expressly qualified in their entirety by the cautionary statements included in this presentation.

The forward-looking statements that are contained in this presentation involve a number of risks and uncertainties and are based on certain assumptions, including but not limited to: the progress, timing and costs related to the execution of the Company’s business plan and strategy; estimates and projections regarding the industry in which the Company operates; the future success of research and development activities; the absence of material changes in general business and economic conditions; estimates regarding the future financing and capital requirements; and the absence of adverse changes in relevant laws and regulations. As a consequence, actual results might differ materially from results forecast or suggested in these forward-looking statements. Please see the Company's most recent Annual Information Form, which is available under the Company's profile on EDGAR at www.sec.gov/edgar and SEDAR+ at www.sedarplus.ca for additional related risks factors that could materially affect the Company's operations and financial results.

Furthermore, forward-looking statements contained herein are made as of the date of this MD&A presentation and the Company disclaims any obligation to update any forward-looking statements, whether as a result of new information, future events or results or otherwise accept as required by applicable securities. There can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements.



Corporate Update

Record earnings

Record quarterly revenue

\$7 Million

- Standout year with Q4 highest quarterly revenue in company history

Expanded profit margins

Profit margin growth – 64%

- Improvement reflects our operational efficiency and disciplined execution
- Driven by overall strong growth, particularly in BioStrand

Corporate Update

Operational efficiency

Record adjusted EBITDA

- Narrowed loss to \$316,000
- Underscores the strategy is working and moving us closer to sustained profitability



Strong growth in Canada

\$4.3 million in sales orders

- Year-over-year sales in Canada increased by 47%
- Quarterly orders up 83%
- Orders from new clients rose 93% YoY and 80% QoQ

Corporate Update

Divestiture initiative update

Final stages



IPA EU Subsidiary



Strategic development

Unified rebrand – next stage of growth

- Capturing our evolution into a Bio-native AI company—integrating AI, data, and advanced lab research to transform drug discovery.

Corporate Update Q4

Strategic collaboration

RIBOPRO

- Collaboration to integrate mRNA-based antigen expression with our *in silico* and wet lab discovery capabilities



Technology strategic collaboration

Expanding AI infrastructure with Vultr and AMD

- Upgrade to integrate AMD MI300X GPUs into the architecture
- Power speed, scalability, reduce costs, increase throughput and support margin expansion

Corporate Update Q4

Undisclosed partnership: oncology research

USD \$8-10 million

- Antibody-drug conjugates (ADCs) and bispecifics antibodies for the treatment of cancer
- Duration 18-24 months



FDA press release - regulatory requirement update

April 2025 – shift toward AI-based research

- FDA phasing out animal testing requirements for monoclonal antibodies
- Aligns directly with our business model

Corporate Update Q4

Expanded market presence

Biologics discovery services introduction in Cambridge, MA

- Extending our geographic reach and service footprint in a core U.S. biotech hub



LENS^{ai} Epitope Mapping validation

Head-to-head study confirms gold-standard performance

- Rivals existing methods in hours instead of weeks
- Head-to-head study against 6 key competing technologies

Corporate Update Q4

Vaccine discovery

Potential Universal Dengue Vaccine

- Highlights power of LENS^{ai} and opens door to additional vaccines and therapies
- Market update: validated-target is structurally stable, safe and capable of activating balanced immune response



GLP-1 Candidate

AI designed GLP-1 peptides independent study results

- Matched or exceeded semaglutide in independent receptor activation studies

Corporate Update Q4

LENS^{ai} Immunogenicity screening validation

Case study confirms superior ADA risk prediction

- Composite score strongly correlates with actual ADA incidence rates
- Outperformed leading benchmark
- Enabling earlier candidate de-risking



NASDAQ update

Regained NASDAQ compliance

- Satisfied \$1.00 minimum bid requirement

Corporate Update Q4

Leadership team additions

Board of Directors

Jon Lieber

- Sr. Executive Officer, 30 years leadership
- Experience in biotechnology and life sciences, including deep expertise in capital markets, corporate development and Nasdaq governance



Advisory Board

Jeff Fried

- InterSystems, Director of Platform Strategy and Innovation
- A visionary in healthcare data architecture and AI innovation




Q4 and Fiscal Year 2025 Year End Financial Update

Highest quarterly revenue to date



All values listed in CAD.


Fiscal year revenue




All values listed in CAD.

Quarterly expenses


Research & Development



Sales & Marketing




General & Administrative



All values listed in CAD.



Improvement of adjusted EBITDA and increased cash



All values listed in CAD.

Q&A

Q4 and FY 2025 Year End Earnings Call



July 29, 2025 | ir.ipatherapeutics.com | NASDAQ: IPA

©2025 ImmunoPrecise Antibodies LTD. All rights reserved. IPA is a trademark of ImmunoPrecise Antibodies LTD. BioStrand is an independently operating subsidiary of ImmunoPrecise Antibodies. BioStrand, LENS[®] and HYFTs are trademarks of BioStrand, BV. Talem is an independently operating subsidiary of ImmunoPrecise Antibodies. Talem is a trademark of Talem Therapeutics LLC.

The HUB of
Biotherapeutic
Intelligence™